Analytical Data
-
基因名
SF3B1
- Application
-
别名
PRP10; PRPF10; SAP155; SF3b155; Spliceosome-associated protein 155; Pre-mRNA-splicing factor SF3b 155 kDa subunit
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75533
-
表达区间
Leu1038~Leu1304
-
分子量
33kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SF3B1 (Splicing Factor 3B Subunit 1) is a critical component of the spliceosome, a complex responsible for the excision of introns from pre-mRNA and the ligation of exons, processes vital for proper gene expression. Mutations in the SF3B1 gene have been associated with various hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). These mutations can lead to aberrant splicing of pre-mRNAs, resulting in the production of dysfunctional proteins that drive oncogenic processes. Research into SF3B1 recombinant proteins focuses on understanding the structural and functional implications of these mutations. By producing and studying SF3B1 in a controlled laboratory environment, scientists aim to elucidate the molecular mechanisms underlying splicing dysregulation in cancer. This research not only provides insights into the pathogenic roles of SF3B1 mutations but also opens up potential avenues for targeted therapies that rectify splicing errors, offering hope for improved treatment strategies in cancer patients. Understanding the interplay between SF3B1 mutations and RNA splicing is crucial for developing biomarkers and therapeutic interventions in malignancies linked to splicing factor dysregulation.
